• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·SKVI
Share

Skinvisible, Inc. Stocks

$ 0.18Last Updated 31.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 972692

$ 0.18
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Skinvisible, Inc., together with its associated entities, specializes in the creation, production, and distribution of advanced polymer-based delivery system technologies. These proprietary systems facilitate the topical, transdermal, and mucosal application of active ingredients, serving various sectors including pharmaceuticals (both prescription and over-the-counter), personal skincare, and cosmetics. Beyond dermatological applications, the company's non-dermatological formulations address specific needs in women's health, pain management, and other diverse markets. Under the 'Skinbrella' brand, Skinvisible provides consumer products such as sunless tanning lotions and sunscreens. Their business model also encompasses licensing these technologies to pharmaceutical and consumer goods companies. Furthermore, they assist pharmaceutical clients with early-stage formulation development. A key service involves reformulating existing pharmaceutical products nearing patent expiration, utilizing their unique Invisicare patent to introduce new product benefits and facilitate line extensions. Incorporated in 1998, the company originally operated as Microbial Solutions, Inc. before adopting the name Skinvisible, Inc. in February 1999. It maintains its headquarters in Las Vegas, Nevada.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 16:01

Small-Cap Highlights: Cathie Wood's Investments, the Sale of Forte Biosciences, and the CBIZ Deal

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026